CSIMarket


Cannapharmarx Inc   (CPMD)
Other Ticker:  
 

Cannapharmarx Inc

CPMD's Fundamental analysis








Cannapharmarx Inc 's sales fell in III. Quarter 2023 from the same quarter a year ago.

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -4.74 %

Cannapharmarx Inc net loss deacreased by in III. Quarter 2023 year on year, Cannapharmarx Inc net loss increased by -57.03 % in III. Quarter 2023 year on year,

More on CPMD's Growth


Cannapharmarx Inc
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Cannapharmarx Inc PEG ratio is at -0.01
Company
PE TTM   
Industry
2020.53
PE TTM    
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.79.


More on CPMD's Valuation
 
 Total Debt (Millions $) 9
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ -
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) -
 Tangible Book Value (Per Share $)

Cannapharmarx Inc
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Cannapharmarx Inc PEG ratio is at -0.01
Company
PE TTM   
Industry
2020.53
PE TTM    
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.79.